Zetagen Therapeutics Announces Peer-reviewed Publication of In-Vivo Dose Optimization Findings for ZetaMast™ (Zeta-MBC-005) for Triple Negative Breast Cancer Liver Metastases
Zetagen identified two concentrations of ZetaMast™ (Zeta-MBC-005) which demonstrated superior effectiveness, reduction in tumor burden, and increased survival rate over control Doxorubicin.
' Patients with disseminated metastatic breast cancer involving the liver, face a poor prognosis and new approaches are urgently needed, ' stated Debasish Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. ' Although some therapies have been designed for direct administration for liver metastases, they have not demonstrated efficacy in significantly improving survival. ZetaMast™ is an innovative therapeutic approach that has demonstrated systemic biological effects potentially extending beyond liver metastases in preclinical models, offering promising potential to enhance outcomes in this setting.'
ZetaMast™ (Zeta-MBC-005) Increased Survival in a Mouse Xenograft Liver Metastases Model. The 4T1, TNBC cell line, tagged with luc2 luciferase (4T1-luc2), was implanted directly into the liver of BALB/c mice. Seven days after tumor inoculation, mice were treated with various concentrations via a single administration of ZetaMast™ (Zeta-MBC-005) (30-, 60-, 120-, 180-, 240-, or 480-μg) in combination with 5-mg/kg doxorubicin. Mice in the Control group received 5 mg/kg of doxorubicin and the ZetaMast™ (Zeta-MBC-005) carrier without Zetagen's small molecule, administered every 72-hours.
ZetaMast™ (Zeta-MBC-005) has the ability to deliver Zetagen's small molecules intratumorally as well as other therapies, avoiding off-target side effects.
'Effective locoregional therapies are likely the key to reducing breast cancer mortality for patients with disseminated metastatic disease and increasing 5-year survival above 31%. If treatments like ZetaMast™ (Zeta-MBC-005) can be given when and where needed, increasing the duration of overall tumor control, which may be enough to tip the balance towards a favorable impact on survival,' stated Bryan S. Margulies, MS, Ph.D., CSO of Zetagen.
To view the ZetaMAST™ (Zeta-MBC-005) dose optimization study results go to https://doi.org/10.1371/journal.pone.0323621.
About ZetaMAST™ (Zeta-MBC-005)
ZetaMast™ (Zeta-MBC-005) is a proprietary drug eluting carrier designed for locoregional administration, controlled release of two small molecules in the treatment of multifocal, unresectable, liver metastases from breast cancer with the potential to increase survival rates.
The USPTO has granted Zetagen a 'Composition of Matter' patent for ZetaMast™ (Zeta-MBC-005), and Zetagen has also submitted a filing to the FDA for Orphan Drug Designation.
Zetagen is finalizing preparations for an FDA IND submission this fall, with a Phase 1b clinical trial set to commence early 2026.
About Zetagen Therapeutics
Zetagen has three novel drugs in development, ZetaMet™ (Zeta-BC-003), for the treatment of metastatic breast cancer to bone, ZetaMast™ (Zeta-MBC-005) for breast cancer liver metastases (BCLM), and (NEW) ZetaPrime™ (Zeta-PBC-007) for the treatment of primary HR+ breast cancer, all with inspiring results. To learn more, visit www.zetagen.com.
The FDA has acknowledged Zetagen's innovative research with multiple Breakthrough Designations, notably ZetaMet™ (Zeta-BC-003). Under FDA and Health Canada (HC) approval through the Expanded Access (Compassionate Use) programs, Zetagen has treated eight patients with ZetaMet™ (Zeta-BC-003), with results featured in several peer-reviewed journals. Furthermore, Zetagen has completed enrollment for its Phase 2a open-label clinical trial focused on treating metastatic breast cancer in the spine.
Zetagen Upcoming Events
Zetagen will attend the 2025 San Antonio Breast Cancer Symposium (SABCS).
Forward-Looking Statements
This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 hours ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Business Wire
9 hours ago
- Business Wire
MedCity News Report Reveals Employers are Turning to AI-Powered, Clinically Integrated Independent Healthcare Navigation to Combat Rising Costs
DUBLIN, Ohio--(BUSINESS WIRE)--As employers face mounting pressure to improve health outcomes while managing rising costs, a new report sponsored by Quantum Health reveals a significant shift in how benefit consultants are advising self-insured employers to build and evaluate healthcare benefit strategies. The 2025 Benefits Sentiment Index, conducted in partnership with MedCity News, offers a data driven look into the top challenges and emerging priorities shaping the benefits landscape. "Independent navigation is accelerating as a central benefits strategy, not only to improve the member experience, but to lower costs, improve value on investment and seamlessly integrate AI-driven innovations with compassionate, human-centered care." Share Now in its third year, the Index surveyed more than 120 experienced benefit consultants and uncovered a growing demand for independent, clinically integrated navigation models and a rising dissatisfaction with traditional carrier-provided services. Among the key findings: 68% of surveyed consultants guide clients away from navigation solutions tied to insurance carriers, instead recommending independent partners citing the need for a stronger member experience, clinical integration and transparency in cost savings. 87% of surveyed consultants report advising on GLP-1 drug coverage, with most recommending restrictions and measurable outcomes to ensure cost-effectiveness. The influence of AI continues to grow, with 72% of consultants surveyed counseling clients on its use in benefits — up significantly from the prior year. 'We're excited to once again collaborate with MedCity News on the Benefits Sentiment Index, bringing forward the key priorities shaping the healthcare benefits landscape,' said Dayne Williams, CEO of Quantum Health. 'This year's findings highlight how independent healthcare navigation is accelerating as a central healthcare benefits strategy — not only to simplify and improve the member healthcare experience, but also to lower costs, improve value on investment and seamlessly integrate AI-driven innovations with compassionate, human-centered care.' Williams added, "As the only navigation solution that engages continuously with providers from the member's first moment of need, we take immediate action to guide care decisions in real time. Leveraging advanced AI and our proprietary Real-Time Intercept® platform, we proactively identify members at critical moments and connect them to the right care at the right time. This approach combines clinical expertise with accelerated intervention — delivering independently validated results, improved health outcomes and a better experience for members.' The report also calls attention to gaps in engagement and personalization, with half of consultants reporting that their clients struggle with fragmented care coordination, lack of centralized access and difficulty engaging employees. Consultants are increasingly seeking solutions that integrate clinical care teams, embed AI for proactive risk detection, and provide seamless connections to behavioral health and social determinants of health support. 'At MedCity News, we're committed to surfacing insights that drive smarter healthcare decisions, and this year's Index does exactly that,' said Ken Montgomery, publisher of MedCity News. 'The data reveals a clear call to action: self-insured employers and their consultants are demanding more from navigation solutions — more clinical integration, more actionable data and more alignment with evolving technologies like AI. We're proud to partner with Quantum Health to spotlight these critical shifts and help advance the conversation on what effective benefits strategy looks like today.' 'The takeaway is clear,' said Williams. 'Employers are no longer satisfied with the status quo. The next chapter of healthcare navigation must be clinically integrated, AI-enabled and relentlessly focused on driving measurable results.' The full 2025 Benefits Sentiment Index is available for download here. About MedCity News MedCity News is the go-to digital destination for B2B healthcare innovation news, informing decision-makers of trends in the healthcare industry. MedCity News produces dynamic and unique innovation-focused events for the entire healthcare ecosystem, gathering experts from across disciplines to address the challenges facing the industry. MedCity News also produces the Debunked videocast, as well as several podcasts: MedCity Pivot, MedCity Moves and MedCity FemFwd. MedCity News is owned by Breaking Media, a network of websites, e-newsletters, events and social media channels for influential, affluent business communities. To learn more visit MedCity News. About Quantum Health Celebrating 25 years of innovation, Quantum Health is a leading consumer healthcare navigation and care coordination company. Its Real-Time Intercept® platform identifies early intervention opportunities to improve engagement, outcomes, and cost efficiency. Based in Dublin, Ohio, Quantum Health has earned national recognition for growth and workplace culture, including honors from FORTUNE, Inc. 5000, and the Women Presidents' Organization. To learn more, visit and connect on LinkedIn.
Business Wire
9 hours ago
- Business Wire
Nu-Tek BioSciences Brings Animal-Free Cell Culture and Fermentation Solutions to BPI East 2025
MINNETONKA, Minn--(BUSINESS WIRE)--Nu-Tek BioSciences, a leading provider of high-performance, 100% animal-free peptones and specialty yeast extracts, announced its participation in next month's BioProcess International (BPI) East Conference & Exhibition. The event will take place from September 15-18, 2025, at the Hynes Convention Center in Boston, MA. Biomanufacturers are invited to connect with Nu-Tek BioSciences to discover their critical ingredients for advancing cell culture and industrial fermentation. Nu-Tek's 100% animal-free cell culture and fermentation ingredients are critical to develop today's leading pharmaceutical products. Share Nu-Tek BioSciences directly supports global biopharmaceutical manufacturers with innovative and sustainable raw materials. The company leverages their purpose-built, dedicated facility to manufacture premium quality peptones and yeast extracts, ensuring consistent quality, supply chain security, and the elimination of risks associated with animal-derived components. "BPI East is an invaluable platform for us to engage with biomanufacturers seeking to optimize their cell culture and industrial fermentation processes," said Chris Wiedel, Chief Business Officer for Nu-Tek BioSciences. "Our 100% animal-free ingredients are designed to meet the rigorous demands of modern biomanufacturing. We look forward to discussing how our products and variability reduction programs support the development and at-scale manufacturing of groundbreaking therapeutics." The Nu-Tek team will be available to provide insights into how Nu-Tek's ingredients enhance cell growth, improve yields, and streamline bioprocessing workflows. More information about Nu-Tek BioSciences products and services can be found at About Nu-Tek BioSciences: Nu-Tek BioSciences is a market leader in the development and manufacturing of high-quality, 100% animal-origin-free (AOF) peptones and protein hydrolysates. Headquartered in Minnetonka, Minnesota, the company operates a state-of-the-art, purpose-built manufacturing facility dedicated to producing superior raw materials for the biopharmaceutical industry. Nu-Tek's innovative solutions are essential for cell culture and microbial fermentation, supporting the production of vaccines, therapeutics, and other vital biologics.
